CHINARES PHARMA(03320) 智通财经网·2025-03-26 04:40Core Points - China Resources Pharmaceutical (03320) reported a net profit attributable to equity holders of 3.351 billion yuan, a decrease of 13.06% year-on-year [1] - The company achieved total revenue of 257.673 billion yuan, an increase of 5.3% year-on-year, with a gross profit of 40.689 billion yuan, up 6.13% [1] - The proposed final dividend is 0.052 yuan per share [1] Revenue Breakdown - The revenue contributions from the three main business segments for 2024 were 16.1% from pharmaceuticals, 80.0% from pharmaceutical distribution, and 3.9% from retail and others [1] - The pharmaceutical segment generated revenue of 46.324 billion yuan, a year-on-year increase of 6.6%, with a gross margin of 59.4%, up 0.3 percentage points [1] - The pharmaceutical distribution segment reported revenue of 213.237 billion yuan, a growth of 5.5%, maintaining a gross margin of 5.9% [1] Retail Business Performance - The retail segment achieved revenue of 10.104 billion yuan, a year-on-year increase of 5.5%, driven by rapid growth in high-value drug direct-to-patient (DTP) business [2] - The DTP business generated approximately 6.9 billion yuan in revenue, reflecting a growth of about 17% [2] - The gross margin for the retail business was 6.2%, down 1.4 percentage points compared to the previous year, primarily due to the increased proportion of lower-margin DTP business [2]